Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-04T21:20:04.622Z Has data issue: false hasContentIssue false

Alternative starting regimen with aripiprazole long-acting treatments, a case report

Published online by Cambridge University Press:  01 September 2022

M. Huete Naval*
Affiliation:
Hospital Clínico San Carlos, Institute Of Psychiatry And Mental Health, Madrid, Spain
B. Serván
Affiliation:
Hospital Universitario Clínico San Carlos, Psychiatry And Mental Health, Madrid, Spain
M.E. Expósito Durán
Affiliation:
Hospital Clínico San Carlos, Instituto De Psiquiatría Y Salud Mental, Madrid, Spain
P. Albarracin
Affiliation:
Hospital Universitario Clínico San Carlos, Psychiatry And Mental Health, Madrid, Spain
E. Herrero Pellón
Affiliation:
Hospital Clínico San Carlos, Institute Of Psychiatry And Mental Health, Madrid, Spain
R. Galerón
Affiliation:
Hospital Clínico San Carlos, Institute Of Psychiatry And Mental Health, Madrid, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Aripiprazole long-acting treatments can significantly control symptom, improve adherence and reduce the risk of relapse compared to oral drugs. An alternative start-up guideline has recently been approved in several countries that simplifies its administration.

Objectives

To present a case report of a patient with schizophrenia treated with alternative starting regimen of aripiprazole long-acting treatment.

Methods

Presentation of a clinical case supported by a non-systematic review of literature.

Results

We present the case of a 22-year-old patient diagnosed with schizophrenia, whose symptoms started after the birth of her son, 2 years ago. She has presented a poor clinical evolution, requiring several admissions to our inpatient service after discontinuation of her medication. The patient has taken different antipsychotics, including olanzapine and paliperidone long-acting treatment, which were suspended due to side effects (weight gain and increased prolactin levels). A switch to oral aripiprazole 20mg was made, which showed good response and tolerance. Given the persistence of irregular intake, it was decided to switch to aripiprazole long-acting treatment, applying an alternative initial regime consisting of two doses of aripiprazole long-acting treatments 400mg and one oral aripiprazole 20mg. The patient has since had no delusions or hallucinations and is living independently at home.

Conclusions

The administration of a simplified initial regime with aripiprazole long-acting treatments could improve therapeutic adherence while maintaining the same effectiveness and similar side effects.

Disclosure

No significant relationships.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.